rs762515373
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The ENST00000370360.8(GLMN):c.157_161del(p.Lys53Ter) variant causes a frameshift change. The variant allele was found at a frequency of 0.0000981 in 1,610,474 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000046 ( 0 hom., cov: 30)
Exomes 𝑓: 0.00010 ( 0 hom. )
Consequence
GLMN
ENST00000370360.8 frameshift
ENST00000370360.8 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.73
Genes affected
GLMN (HGNC:14373): (glomulin, FKBP associated protein) This gene encodes a phosphorylated protein that is a member of a Skp1-Cullin-F-box-like complex. The protein is essential for normal development of the vasculature and mutations in this gene have been associated with glomuvenous malformations, also called glomangiomas. Multiple splice variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 1-92297407-ATTCTT-A is Pathogenic according to our data. Variant chr1-92297407-ATTCTT-A is described in ClinVar as [Pathogenic]. Clinvar id is 7806.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-92297407-ATTCTT-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GLMN | NM_053274.3 | c.157_161del | p.Lys53Ter | frameshift_variant | 3/19 | ENST00000370360.8 | NP_444504.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GLMN | ENST00000370360.8 | c.157_161del | p.Lys53Ter | frameshift_variant | 3/19 | 1 | NM_053274.3 | ENSP00000359385 | P1 | |
GLMN | ENST00000495106.5 | c.157_161del | p.Lys53Ter | frameshift_variant, NMD_transcript_variant | 3/18 | 1 | ENSP00000436829 |
Frequencies
GnomAD3 genomes AF: 0.0000461 AC: 7AN: 151694Hom.: 0 Cov.: 30
GnomAD3 genomes
AF:
AC:
7
AN:
151694
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000477 AC: 12AN: 251380Hom.: 0 AF XY: 0.0000736 AC XY: 10AN XY: 135848
GnomAD3 exomes
AF:
AC:
12
AN:
251380
Hom.:
AF XY:
AC XY:
10
AN XY:
135848
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000104 AC: 151AN: 1458780Hom.: 0 AF XY: 0.000109 AC XY: 79AN XY: 725948
GnomAD4 exome
AF:
AC:
151
AN:
1458780
Hom.:
AF XY:
AC XY:
79
AN XY:
725948
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000461 AC: 7AN: 151694Hom.: 0 Cov.: 30 AF XY: 0.0000405 AC XY: 3AN XY: 74068
GnomAD4 genome
AF:
AC:
7
AN:
151694
Hom.:
Cov.:
30
AF XY:
AC XY:
3
AN XY:
74068
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Glomuvenous malformation Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Oct 06, 2022 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 16, 2022 | The GLMN c.157_161delAAGAA variant (rs762515373) is one of a common variants associated with glomuvenous malformations (Brouillard 2002, Brouillard 2005, Suárez-Magdalena 2019). These reports demonstrated segregation of this variant with disease from over 20 families, and with similar haplotype sharing suggestive of a common ancestral origin. This variant is listed in the Genome Aggregation Database (gnomAD) with a frequency of 0.02 percent in the South Asian population (identified on 6 out of 30,610 chromosomes) and has been reported to the ClinVar database as pathogenic (Variation ID: 7806). This variant causes a frameshift by deleting 5 nucleotides in the third exon (of 19 total exons), and is predicted to result in a truncated protein. Truncating variants in GLMN are a common mechanism of disease. Based on these observations, the c.157_161del is considered to be pathogenic. Pathogenic variants in GLMN are inherited in an autosomal dominant manner and are associated with glomuvenous malformations (MIM: 138000). Reduced penetrance and phenotypic variability are thought to be accounted for by somatic second hit variants, most commonly uniparental isodisomy involving chromosome 1p (Amyere 2013). References: Amyere et al. Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet. 2013 Feb 7;92(2):188-96. doi: 10.1016/j.ajhg.2012.12.017. Epub 2013 Jan 31. Brouillard et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet. 2002 Apr;70(4):866-74. Brouillard et al. Four common glomulin mutations cause two thirds of glomuvenous malformations ("familial glomangiomas"): evidence for a founder effect. J Med Genet. 2005 Feb;42(2):e13. Suárez-Magdalena et al., Glomulin gene c.157_161del mutation in a family with multiple glomuvenous malformations. Int J Dermatol. 2019 Feb;58(2):e43-e45. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 06, 2021 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with glomuvenous malformations (MIM#138000). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0302 - Variant is present in gnomAD (v2) <0.001 for a dominant condition (14 heterozygotes, 0 homozygotes). (SP) 0701 - Other variants predicted to result in NMD comparable to the one identified in this case have very strong previous evidence for pathogenicity (ClinVar, DECIPHER). (SP) 0801 - This variant has very strong previous evidence of pathogenicity in unrelated individuals and is the most common variant in the GLMN gene associated with glomuvenous malformations (ClinVar, PMID: 23801931). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Mar 02, 2023 | This sequence change in GLMN is a frameshift variant predicted to cause a premature stop codon, p.(Lys53*), in biologically relevant exon 3/19 leading to nonsense-mediated decay in a gene in which loss-of-function is an established disease mechanism. The highest population minor allele frequency in the population database gnomAD v2.1 is 0.02% (6/30,610 alleles) in the South Asian population. This variant is the most commonly reported variant causing glomuvenous malformations (PMID: 23801931), and segregates with disease in multiple families (PMID: 11845407, 30460983). Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as PATHOGENIC. Following criteria are met: PVS1, PP1_Strong. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 24, 2022 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 06, 2022 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 30325312, 23801931, 11845407, 30460983, 32538359, 11175297, 31589614) - |
Pathogenic, criteria provided, single submitter | clinical testing | Seattle Children's Hospital Molecular Genetics Laboratory, Seattle Children's Hospital | Dec 09, 2019 | The c.157_161delAAGAA (p.Lys53*) variant is one of the most frequently reported pathogenic GLMN variants, accounting for ~45% of affected individuals (Ref 1-3). The deletion of five nucleotides replaces the lysine with a premature stop codon at position 53 (p.Lys53*). This variant is predicted to result in a loss of gene function. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 01, 2024 | The c.157_161delAAGAA (p.K53*) alteration, located in exon 3 (coding exon 2) of the GLMN gene, consists of a deletion of 5 nucleotides from position 157 to 161, causing a translational frameshift with a predicted alternate stop codon after amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on data from gnomAD, this allele has an overall frequency of 0.005% (14/282026) total alleles studied. The highest observed frequency was 0.02% (6/30610) of South Asian alleles. This variant has been reported in multiple individuals with glomuvenous malformations and has been to show to segregate with the phenotype in multiple large families (Brouillard, 2002; Brouillard, 2013; Suárez-Magdalena, 2019). Based on the available evidence, this alteration is classified as pathogenic. - |
GLMN-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 03, 2024 | The GLMN c.157_161del5 variant is predicted to result in premature protein termination (p.Lys53*). This variant has been reported to be causative for autosomal dominant glomuvenous malformations in multiple families (referred to as 157delAAGAA - Brouillard et al. 2002. PubMed ID: 11845407). This variant is reported in 0.019% of alleles in individuals of South Asian in gnomAD. Loss-of-function variants in GLMN are a known cause of disease (Brouillard et al. 2013. PubMed ID: 23801931). This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at